MGMT (O-6-methylguanine-DNA methyltransferase) Methylation Detection
The MGMT (O6-methylguanine-DNA methyltransferase) gene encodes a DNA repair protein/enzyme involved in alkylated DNA repair. In gliomas, the MGMT gene is silenced by promoter hypermethylation, impeding transcription, and thus resulting in a decreased expression of the MGMT protein. MGMT promoter hypermethylation has been found in up to 40 % of primary glioblastomas and 40– 60 % of secondary glioblastomas. Such hypermethylation is also present in other diffuse gliomas, including 60-93% of oligodendrogliomas.
This epigenetic modification has been associated with an increased tumor sensitivity to alkylating chemotherapy. In alkylating therapies such as temozolamide, a methyl group is added to the O6-position of the nucleotide guanine, resulting in DNA damage and apoptosis. Due to reduced expression of the protein secondary to the promoter hypermethylation, the cell has a decreased ability to repair alkylated DNA. Therefore, MGMT expression analysis is often used to predict which tumors may have a more favorable response to alkylating chemotherapeutic agents. Additionally, MGMT methylation status has been identified as a strong, independent favorable predictor of survival in glioblastoma patients receiving alkylating chemotherapy.
The most common method utilized to assess the MGMT promoter methylation status is a methylation-specific PCR analysis, which applies primers composed of differing quantities of CpG sites to allow differentiation between methylated and unmethylated DNA. Methylation-specific pyrosequencing is another technique that may be used and has shown good sensitivity. Other less commonly used DNA-based methods are available such as combined bisulfite restriction analysis (COBRA) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA).
- For prognostic and predictive value of newly diagnosed glioblastomas
- Guiding therapy decision making for newly diagnosed glioblastomas in elderly patients (>60 years)
If the tumor is negative for MGMT promoter methylation, the result is an unfavorable prognostic factor for patients with glioblastoma.
Lack of methylation also suggests that alkylating therapies may have limited value for the particular patient
If results are positive for MGM promoter methylation, the result is a favorable prognostic factor for patients with glioblastoma.
Additionally, MGMT promoter methylation predicts a positive response to alkylating chemotherapy (i.e. temozolomide)
MGMT promoter methylation absent (Negative for MGMT promoter methylation)
Formalin-fixed, paraffin-embedded (FFTE) tissue blocks and slides.
Fixed tissues and FFTE are stable for long at room temperature.
- J Cell Physiol. 2018 Jan;233(1):378-386. [PMID: 28266716]
- N Engl J Med. 2000 Nov 9;343(19):1350-4. [PMID: 11070098]
- J Clin Oncol. 2006 Jul 20;24(21):3431-7. [PMID: 16849758]
- Arch Pathol Lab Med. 2011 May;135(5):558-68. [PMID: 21526954]
- Neuro Oncol. 2010 Feb;12(2):116-21. [PMID: 20150378]
- Nat Rev Neurol. 2014 Jul;10(7):372-85. [PMID: 24912512]
- Lancet Oncol. 2012 Sep;13(9):916-26. [PMID: 22877848]